Brief: Medicenna Strengthens IP Protection For MDNA11, BiSKITS Programs
05/01/2023 15:50
Jan 5 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA STRENGTHENS INTELLECTUAL PROPERTY PROTECTION FOR
MDNA11 AND BISKITS™ PROGRAMS WITH ISSUANCE OF U.S. PATENT
* MEDICENNA THERAPEUTICS CORP - U.S. PATENT'S TERM EXTENDS
INTO
AT LEAST 2039 WITHOUT ACCOUNTING FOR ANY POTENTIAL EXTENSIONS
Source text for Eikon: ID:nGNX7nd4Yz
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results